Amgen Inc. $AMGN Shares Sold by Horizon Investments LLC

Key Points

• Horizon Investments cut its stake in Amgen by 41.3% in Q4, selling 24,091 shares and retaining 34,226 shares worth $11.203 million per its latest 13F filing.
• Amgen beat Q1 expectations with $5.15 EPS (vs. $4.77 est.) and $8.62B revenue, and issued FY‑2026 EPS guidance of $21.70–$23.10 (consensus ~22.28).
• Dividend announced: Amgen declared a quarterly dividend of $2.52 (ex‑dividend May 15, payable June 5), annualized to $10.08 for a ~3.1% yield.

Horizon Investments LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 41.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,226 shares of the medical research company's stock after selling 24,091 shares during the quarter. Horizon Investments LLC's holdings in Amgen were worth $11,203,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Capital World Investors raised its holdings in Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after buying an additional 1,935,876 shares during the period. Vanguard Group Inc. raised its holdings in Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock valued at $17,949,296,000 after buying an additional 961,975 shares during the period. National Bank of Canada FI raised its holdings in Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company's stock valued at $346,076,000 after buying an additional 863,216 shares during the period. Van ECK Associates Corp raised its holdings in Amgen by 71.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company's stock valued at $383,254,000 after buying an additional 567,400 shares during the period. Finally, Fisher Asset Management LLC raised its holdings in Amgen by 91.6% in the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company's stock valued at $221,607,000 after buying an additional 375,463 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Down 4.7%

Shares of NASDAQ:AMGN opened at $329.82 on Friday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market capitalization of $178.00 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 3.26 and a beta of 0.44. The firm's 50-day moving average is $358.07 and its two-hundred day moving average is $340.79. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 139.90%. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts predict that Amgen Inc. will post 22.28 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen's dividend payout ratio is 70.84%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AMGN. Truist Financial boosted their price objective on shares of Amgen from $325.00 to $327.00 and gave the company a "hold" rating in a report on Friday. Citigroup boosted their price objective on shares of Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an "outperform" rating in a report on Thursday, January 29th. Barclays began coverage on shares of Amgen in a report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 price objective on the stock. Finally, Morgan Stanley set a $332.00 price objective on shares of Amgen in a report on Friday. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Amgen has an average rating of "Hold" and a consensus target price of $357.54.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.